Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: PBMC DNA methylation in patients with myeloma from the BMT CTN 0702 (STaMINA) phase 3 trial.

Data availability

The clinical data that support the findings of this study are publicly available at BioLINCC: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant With Lenalidomide Maintenance for Patients With Multiple Myeloma (0702) ( DNA methylation data will be shared upon reasonable request with the corresponding author.


  1. D’Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, et al. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. Am J Hematol. 2022.

  2. Bartlett AH, Liang JW, Sandoval-Sierra JV, Fowke JH, Simonsick EM, Johnson KC, et al. Longitudinal study of leukocyte DNA methylation and biomarkers for cancer risk in older adults. Biomark Res. 2019;7:10.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Joyce BT, Gao T, Zheng Y, Liu L, Zhang W, Dai Q, et al. Prospective changes in global DNA methylation and cancer incidence and mortality. Br J Cancer. 2016;115:465–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Rodriguez RM, Suarez-Alvarez B, Salvanes R, Muro M, Martinez-Camblor P, Colado E, et al. DNA methylation dynamics in blood after hematopoietic cell transplant. PLoS One. 2013;8:e56931.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wong Doo N, Makalic E, Joo JE, Vajdic CM, Schmidt DF, Wong EM, et al. Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms. Epigenomics. 2016;8:55–66.

    Article  CAS  PubMed  Google Scholar 

  6. Muylaert C, Van Hemelrijck LA, Maes A, De Veirman K, Menu E, Vanderkerken K, et al. Aberrant DNA methylation in multiple myeloma: a major obstacle or an opportunity? Front Oncol. 2022;12:979569.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial. J Clin Oncol. 2019;37:589–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Pan H, Renaud L, Chaligne R, Bloehdorn J, Tausch E, Mertens D, et al. Discovery of candidate DNA methylation cancer driver genes. Cancer Discov. 2021;11:2266–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Chakraborty R, Hamilton BK, Hashmi SK, Kumar SK, Majhail NS. Health-related quality of life after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2018;24:1546–53.

  10. Cerutti J, Lussier AA, Zhu Y, Liu J, Dunn EC. Associations between indicators of socioeconomic position and DNA methylation: a scoping review. Clin Epigenetics. 2021;13:221.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


This ancillary study was funded by a Froedtert & MCW Cancer Center grant (project 3379013). AD is supported by K23 HL141445. The BMT CTN 0702 was supported by Grant No. U10HL069294 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute; by Celgene Corporation and Millennium (Takeda) Pharmaceuticals; and by The Alliance for Clinical Trials in Oncology, the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group, and SWOG. The content of this article is solely the responsibility of the authors and does not represent the official views of the funding parties.

Author information

Authors and Affiliations



AD designed the study, obtained funding, reviewed the analysis, and wrote the manuscript. RB designed and conducted the biostatistical analysis, and edited the manuscript. BQT conducted biostatistical analysis. GY, HU and SJ conducted the DNA methylation assays, reviewed the analysis, and edited the manuscript. JD and MBD reviewed the analysis and edited the manuscript. MCP (Protocol Officer, BMT CTN 0702), SG, HL, ES (Protocol Co-Chair, BMT CTN 0702), and AK (Protocol Co-Chair, BMT CTN 0702) led the BMT CTN 0702 study and/or were from the top 3 centers that provided data contributing to this study, reviewed the current analysis, and edited the manuscript. All authors approved the final manuscript draft.

Corresponding author

Correspondence to Anita D’Souza.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

D’Souza, A., Brazauskas, R., Teng, B.Q. et al. DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma. Bone Marrow Transplant 58, 334–336 (2023).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links